Alexion On Its AstraZeneca Integration And Growth Plan

An Interview With Senior VP-US Commercial Operations Scott Weintraub

Two years after being acquired by AstraZeneca, the company remains relatively autonomous in rare disease, but with “bridges” to its big pharma parent.

merging
Alexion discussed its integration into AstraZeneca • Source: Shutterstock

Two years after AstraZeneca PLC completed the acquisition of the rare disease specialist Alexion Pharmaceuticals Inc., the companies have started executing on a combined growth strategy, with Alexion left to lead the charge in rare diseases.

Key Takeaways
  • US commercial head Scott Weintraub talked to Scrip in an interview at the company’s Boston headquarters.

Alexion recently held an event at its Boston headquarters to shine a spotlight on rare diseases, and afterwards senior VP-US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.